Patents Assigned to Amgen
  • METHODS FOR TREATING LEUKEMIA
    Publication number: 20220389099
    Abstract: The present invention relates to treatment methods for leukemia using bispecific antibody constructs that specifically bind to human CD33 and human CD3. In particular, the present invention relates to methods for treating myeloid leukemia, including relapsed/refractory myeloid leukemia, in a patient in need thereof comprising administering to the patient at least one initiation cycle and at least one maintenance cycle of an anti-CD33×anti-CD3 bispecific antibody construct, wherein each initiation cycle and maintenance cycle comprises administering the bispecific antibody construct according to specific dosage regimens. Pharmaceutical compositions comprising the bispecific antibody constructs for use in the methods are also disclosed.
    Type: Application
    Filed: November 3, 2020
    Publication date: December 8, 2022
    Applicant: AMGEN INC.
    Inventors: Suresh AGARWAL, Sophia KHALDOYANIDI, Dirk NAGORSEN, Vijay UPRETI
  • Anti-PD-1 antibodies and methods of treatment
    Patent number: 11518808
    Abstract: Provided herein are PD-1 antigen-binding proteins and related nucleic acids, vectors, host cells, kits and pharmaceutical compositions. Methods of making PD-1 antigen-binding proteins and methods of treating a subject are further provided.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: December 6, 2022
    Assignee: Amgen Inc.
    Inventors: Khaled M. K. Z. Ali, Neeraj Jagdish Agrawal, Gunasekaran Kannan, Ian Foltz, Zhulun Wang, Daren Bates, Marissa Mock, Shunsuke Takenaka
  • Drug delivery device with vacuum assisted securement and/or feedback
    Patent number: 11517663
    Abstract: A drug delivery device includes a housing with at least one pressure communication channel or aperture, which distributes a negative fluid pressure across its base to draw tissue against the device. The device can also include a porous, adhesive layer over the channel(s) or aperture(s), for attaching to tissue. The device can also include a pressure sensor for determining whether there is proper attachment. Further, a bladder may be used instead of the adhesive layer for attaching the device. The bladder, in a partially inflated state, can apply constant pressure across a contact surface causing a flexible adhesive layer attached to the bladder to confirm and adhere to the tissue. Subsequent evacuation of the bladder causes it to deflate and collapse or retract, thereby causing the flexible adhesive layer to pull and stretch the tissue toward the base.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: December 6, 2022
    Assignee: AMGEN INC.
    Inventors: Adam B. McCullough, Lawrence S. Ring
  • DOSING OF KRAS INHIBITOR FOR TREATMENT OF CANCERS
    Publication number: 20220378787
    Abstract: Provided herein are methods of administering a KRAS G12C inhibitor to a cancer subject.
    Type: Application
    Filed: July 22, 2022
    Publication date: December 1, 2022
    Applicant: Amgen Inc.
    Inventors: Haby HENARY, James Russell LIPFORD, VIctor J. CEE
  • Body contour adaptable autoinjector device
    Patent number: 11511051
    Abstract: An injector for delivering a therapeutic product may include a base having a flexible surface that conforms to various body contours of a patient and defines one or more an injection chambers. The injector may have a height that is substantially less than its width, thereby defining a low profile, which provides a larger more stable base that can pinch or stretch the skin in a controlled manner. The larger base can also accommodate larger volumes via multiple injection chambers and/or large combined primary containers.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: November 29, 2022
    Assignee: AMGEN INC.
    Inventors: Mark Ka Lai Lee, Stephanie Toy, Valerie M. Fenster
  • Heterocyclic compounds as Delta-5 desaturase inhibitors and methods of use
    Patent number: 11512097
    Abstract: The present disclosure provides compounds useful for the inhibition of Delta-5 Desaturase (“D5D”). The compounds have a general Formula I wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a metabolic or cardiovascular disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: November 29, 2022
    Assignee: AMGEN INC.
    Inventors: Jennifer R. Allen, Michela Beltrani, Matthew P. Bourbeau, Teodora P. Damyanova, Iain Lingard, Ana E. Minatti, Paolo Vincetti
  • HIGH SALT WASHES DURING CATION EXCHANGE CHROMATOGRAPHY TO REMOVE PRODUCT-RELATED IMPURITIES
    Publication number: 20220372071
    Abstract: The invention relates to methods for removal of low isoelectric point product-related impurities during cation exchange purification operations.
    Type: Application
    Filed: November 4, 2020
    Publication date: November 24, 2022
    Applicant: AMGEN INC.
    Inventors: Malhar R. AMBHAIKAR, Luis DIAZ, Natalia R. GOMEZ, Benjamin J. TILLOTSON
  • HIGH SALT LOAD CONDITIONING DURING CATION EXCHANGE CHROMATOGRAPHY TO REMOVE PRODUCT-RELATED IMPURITIES
    Publication number: 20220372070
    Abstract: The invention relates to high salt load conditioning during cation exchange chromatography for removal of low isoelectric point product-related impurities during manufacture of recombinant multispecific proteins.
    Type: Application
    Filed: November 4, 2020
    Publication date: November 24, 2022
    Applicant: AMGEN INC.
    Inventors: Luis DIAZ, Natalia R. GOMEZ
  • KIF18A INHIBITORS
    Publication number: 20220372018
    Abstract: Amide compounds of formula (I): as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.
    Type: Application
    Filed: August 3, 2020
    Publication date: November 24, 2022
    Applicant: AMGEN INC.
    Inventors: Nuria A. TAMAYO, Abhisek BANERJEE, Jian Jeffrey CHEN, Matthew Richard KALLER, Thomas T. NGUYEN, Nobuko NISHIMURA, Qiufen May XUE, John Gordon ALLEN, Michael J. FROHN
  • Antibodies binding to soluble BCMA
    Patent number: 11505614
    Abstract: The present invention relates to antibodies that bind to soluble BCMA (sBCMA). Moreover, the invention relates to a detection system comprising such antibodies. The antibodies or the detection system may be used for detecting or quantifying sBCMA, for diagnosing a disease associated with sBCMA, for patient stratification, monitoring disease progression, and evaluating the therapeutic response.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: November 22, 2022
    Assignee: AMGEN INC.
    Inventors: Agnieszka Kielczewska, Brian Chan
  • Method of treating diseases using an IL-17 receptor antibody formulation
    Patent number: 11505612
    Abstract: The present disclosure relates to AM-14 pharmaceutical formulations and therapeutic dosing regimens for the treatment of disease.
    Type: Grant
    Filed: September 8, 2020
    Date of Patent: November 22, 2022
    Assignee: AMGEN K-A, INC.
    Inventors: Dingjiang Liu, Holly Zhuohong Huang, David Andrew Martin, Christopher Boyd Russell, David H. Salinger, Scott Walter Baumgartner, Christopher Endres
  • N-CYANO-7-AZANORBORNANE DERIVATIVES AND USES THEREOF
    Publication number: 20220363694
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Application
    Filed: August 13, 2019
    Publication date: November 17, 2022
    Applicants: Amgen Inc., Carmot Therapeutics, Inc.
    Inventors: John R. BUTLER, Daniel ERLANSON, Russell GRACEFFA, Jeffrey IWIG, Joon Won JEONG, Ryan D. WHITE, Yongwei WU, Shuyan YI, Xiao Mei ZHENG, Jesse M. MCFARLAND, Abhisek BANERJEE
  • PURIFICATION METHODS FOR CARBOHYDRATE-LINKED OLIGONUCLEOTIDES
    Publication number: 20220363711
    Abstract: The present invention relates to methods for purifying nucleic acids. In particular, the present invention relates to methods for purifying carbohydrate-conjugated oligonucleotides using a mixed-mode stationary phase and a mobile phase comprising a dual salt/organic solvent gradient. Methods for purifying carbohydrate-conjugated oligonucleotides using an anion exchange stationary phase and a mobile phase comprising a dual pH/salt gradient are also described.
    Type: Application
    Filed: June 24, 2020
    Publication date: November 17, 2022
    Applicant: AMGEN INC.
    Inventors: Artaches KAZARIAN, Wesley BARNHART
  • METHODS FOR INCREASING MANNOSE CONTENT OF RECOMBINANT PROTEINS
    Publication number: 20220364137
    Abstract: The present invention relates to methods of upregulating the high mannose glycoform content of a recombinant protein during a mammalian cell culture by manipulating the mannose to total hexose ratio in the cell culture media formulation.
    Type: Application
    Filed: July 18, 2022
    Publication date: November 17, 2022
    Applicant: Amgen Inc.
    Inventors: Chung-Jr HUANG, Xiaoming YANG
  • ANTI-CGRP RECEPTOR/ANTI-PAC1 RECEPTOR BISPECIFIC ANTIGEN BINDING PROTEINS
    Publication number: 20220363770
    Abstract: The present invention relates to antagonist antibodies of the human calcitonin gene-related peptide (CGRP) receptor as well as bispecific antigen binding proteins derived from the anti-CGRP antibodies that bind to and inhibit both the human CGRP receptor and another target, such as the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) receptor. Pharmaceutical compositions comprising the anti-CGRP receptor antibodies and bispecific antigen binding proteins as well as methods for producing them are also disclosed. Methods of using the anti-CGRP receptor antibodies and bispecific antigen binding proteins to ameliorate, treat, or prevent conditions associated with the CGRP and PAC1 receptors, such as chronic pain, migraine, and cluster headache, are also described.
    Type: Application
    Filed: June 26, 2020
    Publication date: November 17, 2022
    Applicant: AMGEN INC.
    Inventors: Irwin CHEN, Su CHONG, Fernando GARCES, Mark Leo MICHAELS, Christopher MOHR, Kenneth William WALKER, Zhulun WANG, Neeraj Jagdish AGRAWAL, Bryna FUCHSLOCHER, Kevin GRAHAM, Agnes Eva HAMBURGER, Derek E. PIPER, Cen XU
  • Camera-based drug container inspection
    Patent number: 11499922
    Abstract: An inspection system for a drug container is provided to identify foreign matter, such as particles or fibers, within the drug container prior to filling with a drug. The system includes a camera device aligned with an axis of the drug container and captures a series of images of an interior surface of a sidewall of the drug container while the robot causes relative movement between the drug container and the camera device along a linear path. Atypical lighting, which improves contrast between particles and the background in images is employed to aid detection. A control circuit then processes the series of images to identify foreign matter within the drug container.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: November 15, 2022
    Assignee: AMGEN INC.
    Inventors: Thomas C. Pearson, Neelima Chavali, Dmitry Fradkin, Graham F. Milne, Erwin Freund
  • Antibody constructs for CDH19 and CD3
    Patent number: 11498964
    Abstract: The invention provides a bispecific antibody construct comprising a first human binding domain capable of binding to human CDH19 on the surface of a target cell and a second domain capable of binding to human CD3 on the surface of a T cell. Moreover, the invention provides a nucleic acid encoding the antibody construct, a vector comprising the nucleic acid and a host cell transformed or transfected with the vector. Furthermore, the invention provides a process for the production of the bispecific antibody construct, a medical use of the antibody construct and a kit comprising the antibody construct. The bispecific antibody construct may be useful in the treatment of melanoma.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: November 15, 2022
    Assignees: AMGEN RESEARCH (MUNICH) GMBH, AMGEN INC.
    Inventors: Shouhua Xiao, Zheng Pan, Dineli Wickramasinghe, M. Shawn Jeffries, Chadwick Terence King, Brian Mingtung Chan, Peter Kufer, Ralf Lutterbüse, Tobias Raum, Patrick Hoffmann, Doris Rau, Roman Kischel, Bryan Lemon, Holger Wesche
  • Methods and apparati for nondestructive detection of undissolved particles in a fluid
    Patent number: 11501458
    Abstract: The apparati, methods, and computer program products disclosed herein can be used to nondestructively detect undissolved particles, such as glass flakes and/or protein aggregates, in a fluid in a vessel, such as, but not limited to, a fluid that contains a drug.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: November 15, 2022
    Assignee: AMGEN INC.
    Inventors: Graham F. Milne, Erwin Freund, Ryan L. Smith
  • METHODS FOR HARVESTING MAMMALIAN CELL CULTURES
    Publication number: 20220356502
    Abstract: The invention provides methods and materials for culturing mammalian cells and harvesting recombinant protein.
    Type: Application
    Filed: May 17, 2022
    Publication date: November 10, 2022
    Applicant: AMGEN INC.
    Inventors: Chetan GOUDAR, Sean COLE, Nicole SABO, Henry LIN, Jonathan LULL, Tharmala THARMALINGAM
  • Removal of leaked affinity purification ligand
    Patent number: 11492372
    Abstract: The invention provides for the removal of a large fraction of contaminants from protein preparations while maintaining a high level of recovery using tentacle anion exchange matrix chromatography medium. Using the methods of the invention, leached affinity chromatography contaminants can be removed from recombinant protein preparations.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: November 8, 2022
    Assignee: AMGEN INC.
    Inventors: Samuel Ray Trejo, Robert Perry Brake